Rucaparib or Physician's Choice in Metastatic Prostate Cancer

Cancers, Free Full-Text

PDF] Trial of rucaparib in prostate indications 3 (TRITON3): An international, multicenter, randomized, open-label phase 3 study of rucaparib vs physician's choice of therapy for patients (Pts) with metastatic castration-resistant prostate cancer (

Prostate cancer and PARP inhibitors: progress and challenges, Journal of Hematology & Oncology

Rucaparib provides better survival than usual care in metastatic prostate cancer - Hospital Pharmacy EuropeHospital Pharmacy Europe

The Latest Developments on PARP Inhibitors for Prostate Cancer Treatment

Platinum-based chemotherapy in metastatic prostate cancer: what possibilities?

Guidelines for Management of treating Rucaparib

Rucaparib or physician's choice in metastatic prostate cancer - UROONCO Prostate Cancer

Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium

Recent Advances in the Management of Metastatic Prostate Cancer

Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer - Gonzalez - 2021 - The Journal of Pathology: Clinical Research - Wiley Online Library

Optimizing Therapeutic Strategies in Castration-Resistant Prostate Cancer